China-Based WuXi Biologics Selects Cranbury, New Jersey for Third U.S. Clinical Manufacturing Campus
06/10/2020
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
According to company officials, the New Jersey clinical manufacturing facility will include 6000 L bioreactors, Process Development, Quality Control labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
WuXi Biologics, a Hong Kong-listed company, noted it is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
Most Read
-
-
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Q4 2019
-
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
Q3 2019
-
A Heightened Focus on Reshoring
Q3 2020
-
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
Q3 2020
-
COVID-19 and Site Selection in the Near and Long Term
Q2 2020
-
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Q1 2020